Cardiac-Targeted AAV5-S100A1 Gene Therapy Protects Against Adverse Remodeling and Contractile Dysfunction in Postischemic Hearts
Providing the clinically relevant proof of concept for AAV5 to effectively transduce healthy and dysfunctional human-sized hearts, its clinical long-term safety, scalable producibility, and low preexisting immunity in humans may predestine AAV5 as an effective and safe gene carrier for a prevalent disease such as chronic heart failure, using therapeutic genetic effectors such as <i>hS100A1</i> or others.
Authors
- Julia Ritterhoff (ORCID: https://orcid.org/0000-0002-3419-4830)
- Norbert Frey (ORCID: https://orcid.org/0000-0001-7611-378X)
- Florian André (ORCID: https://orcid.org/0000-0003-1428-2611)
- Jennifer Birkenstock
- Dorothea Kehr
- Erhe Gao (ORCID: https://orcid.org/0000-0002-5151-7857)
- Hugo A. Katus (ORCID: https://orcid.org/0000-0002-2293-2314)
- Andreas Jungmann
- Patrick Most (ORCID: https://orcid.org/0000-0002-3604-2419)
- Karsten Peppel (ORCID: https://orcid.org/0009-0003-0394-6176)
- Janek Salatzki (ORCID: https://orcid.org/0000-0003-1421-474X)
- Karl Varadi
- Walter J. Koch (ORCID: https://orcid.org/0000-0002-8522-530X)
- Johannes Riffel (ORCID: https://orcid.org/0000-0001-5430-8930)
- Helga Pfannkuche
- Martin Busch (ORCID: https://orcid.org/0000-0002-2717-7063)
- Philipp Schlegel (ORCID: https://orcid.org/0000-0003-3888-6655)
- Birgit Seger
Institutions
- Thomas Jefferson University (US)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- CSL (United States) (US)
- DKFZ-ZMBH Alliance (DE)
- Jisc (GB)
- Temple University (US)
- Leipzig University (DE)
Publication Details
- Journal
- Circulation Heart Failure
- Published
- 2025-06-19
- DOI
- https://doi.org/10.1161/circheartfailure.124.012479
- Citations
- 2
- Primary Topic
- Viral Infections and Immunology Research
- Type
- article
- Field-Weighted Citation Impact
- 2.78